EUVIMEDEUVIMED entdecken
Validierungsstudie

Relapse Rate After Glucocorticoid‐Free Remission in Patients With Idiopathic Inflammatory Myopathies and Validation of the International Myositis Assessment and Clinical Studies Group Criteria for Complete Clinical Response and Worsening

Hideaki Tsuji iD, Fabricio Espinosa-Ortega iD, Irene Peralta Garcia, Maryam Dastmalchi, Ingrid E Lundberg iD, Karin Lodin

Arthritis & Rheumatology · 2026

DOI: 10.1002/art.43429 ↗

Kurz gefasst

Validierungsstudie in der Zeitschrift Arthritis & Rheumatology, 2026. Verfasst von Hideaki Tsuji und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Rheumatology, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden. Hauptthemen laut MEDLINE: Myositis, Glucocorticoids, Immunosuppressive Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: The Swedish Rheumatism Association, The Swedish Research Council, Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Our aim was to explore maintenance of glucocorticoid‐free remission in patients with idiopathic inflammatory myopathy (IIM). Additionally, we examined the performance of the International Myositis Assessment and Clinical Study Group (IMACS) criteria for complete clinical response and flare/worsening.

Methods

Patients achieving physician‐determined glucocorticoid‐free remission were extracted from the Swedish Rheumatology Quality Register (SRQ). Relapse rates and associated factors were analyzed. To assess the performance of complete clinical response criteria, IMACS core set measures were evaluated within six months before and after remission. Relapse was defined as IMACS criteria of worsening in IMACS core set measures over 20% to 30% during every visit or in the period from remission to a time point with worsening (modified definition) or glucocorticoid/immunosuppressant administration. Changes from remission to all subsequent visits were compared. The visit with the largest change was chosen as the worse time point (modified definition).

Results

Of 494 patients, 159 (32%) achieved physician‐determined glucocorticoid‐free remission. The 12‐year cumulative relapse rate was 76%, with anti‐Jo1 as a risk factor. From time of remission to six months after remission, IMACS complete clinical response fulfillment rates were as follows: creatine kinase, 23%; Health Assessment Questionnaire, 50%; patient global assessment, 70%; physician global assessment, 80%; extramuscular activity, 83%; and Manual Muscle Test 8, 95%. Only 50% of relapses could be captured by the IMACS worsening definition, but additional relapses were captured by a modified IMACS worsening definition (15%) or by reintroduction of glucocorticoid/immunosuppressant treatment (35%).

Conclusion

Relapses were frequent in patients with IIM after achieving glucocorticoid‐free remission and required management of therapy. IMACS criteria for complete clinical response/worsening need to be amended.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MyositisGlucocorticoidsImmunosuppressive AgentsHumansMaleFemaleRecurrenceMiddle AgedRemission InductionAgedAdultSwedenRegistriesDisease Progression

Substanzen

GlucocorticoidsImmunosuppressive Agents

Autor:innen und Institutionen

  • Division of Rheumatology, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden.
  • Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  • Department of Gastroenterology, Dermatology, Rheumatology, Theme Inflammation and Aging, Karolinska University Hospital, Stockholm, Sweden.

ORCID-Profile: Hideaki Tsuji, Fabricio Espinosa-Ortega, Ingrid E Lundberg

Förderung

  • The Swedish Rheumatism Association
  • The Swedish Research Council
  • Japan Society for the Promotion of Science
  • Stiftelsen Konung Gustaf V:s 80-årsfond
  • Hjärt-Lungfonden
  • ALF project
  • King Gustaf V:th 80-Year Foundation

Zitieren

APA

Tsuji, H., Espinosa-Ortega, F., Peralta Garcia, I., Dastmalchi, M., Lundberg, I. E., & Lodin, K. (2026). Relapse Rate After Glucocorticoid‐Free Remission in Patients With Idiopathic Inflammatory Myopathies and Validation of the International Myositis Assessment and Clinical Studies Group Criteria for Complete Clinical Response and Worsening. Arthritis & Rheumatology. https://doi.org/10.1002/art.43429

Vancouver

Tsuji H, Espinosa-Ortega F, Peralta Garcia I, Dastmalchi M, Lundberg IE, Lodin K. Relapse Rate After Glucocorticoid‐Free Remission in Patients With Idiopathic Inflammatory Myopathies and Validation of the International Myositis Assessment and Clinical Studies Group Criteria for Complete Clinical Response and Worsening. Arthritis & Rheumatology. 2026. doi:10.1002/art.43429

BibTeX
@article{Tsuji2026,
  author = {Tsuji, Hideaki and Espinosa-Ortega, Fabricio and Peralta Garcia, Irene and Dastmalchi, Maryam and Lundberg, Ingrid E and Lodin, Karin},
  title = {Relapse Rate After Glucocorticoid‐Free Remission in Patients With Idiopathic Inflammatory Myopathies and Validation of the International Myositis Assessment and Clinical Studies Group Criteria for Complete Clinical Response and Worsening},
  journal = {Arthritis & Rheumatology},
  year = {2026},
  doi = {10.1002/art.43429}
}
Kostenlos starten →